Tackling Immune Resetting in Multiple Sclerosis Through Translating CNS-Targeted B-Cell Depletion into Long-Term Remission
- Understanding the therapeutic promise of CAR-T through its ability to cross the blood-brain barrier to achieve immune reset by eliminating the CNS-resident B-cells driving progressive MS pathology
- Leveraging the immune-resetting potential through early intervention to prevent the accumulation of permanent disability rather than treating symptoms of a late-stage progressive disease
- Establishing the clinical trial endpoints and regulatory frameworks necessary to prove the durable, long-term benefit and commercial viability of single-dose, curative therapies in a diverse patient population